BDRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Biodexa Pharmaceuticals Plc
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 27, 2026
$0.39−0.07 (-14.36%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2014 to 2025
Gross margin
–
Operating margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | 2.39 | 3.10 | 2.03 | |
| Interest coverage | -132.2× | -53.5× | -37.8× | |
| Inventory turnover | -7.7× | – | – | |
| Capex to revenue | 101.8% | 60.9% | – | |
| Diluted shares | 0M | 2M | 54.86B |
Where the cash went
Fiscal 2021 to 2025, five years combined
Biodexa Pharmaceuticals generated £37.73M from operations and spent £419.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
£37.73M
Used
£419.00K
Capital expenditure£419.00K100%Dividends£00%Share buybacks£00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 3 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-£5.59M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-£5.59M vs –
- Less leverageLong-term debt to assets fell0.8% → –
- Better liquidityCurrent ratio rose1.75 → 2.03
- No dilutionShare count did not rise4.95B → 54.86B
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –